bristol myers cobenfy news

U.S. Regulator Approves Bristol Myers Squibb’s (NYSE:BMY) Schizophrenia Drug

Shares of pharmaceutical company Bristol Myers Squibb ($BMY) are up 4% on news that the U.S. Food and Drug Administration (FDA) has approved its

bovnews · 1h

BMY’s Latest Twist: What’s Fueling the Unexpected Shifts in Bristol-Myers Squibb Co’s Stock Price?

On Friday, Bristol-Myers Squibb Co (BMY) stock saw a modest uptick, ending the day at $50.91 which represents a slight increase of $0.79 or 1.58% from the prior close of $50.12. The stock opened at $51.

Investopedia · 3d

Bristol Myers Squibb Stock Rises After Schizophrenia Drug Gets FDA Approval

Bristol Myers Squibb shares rose Friday, a day after its schizophrenia drug was approved for use by the Food and Drug Administration.

Bristol-Myers Squibb Likely To Revalue Higher Following New Drug Approval

Bristol-Myers Squibb's stock is set to rise with FDA approvals, acquisitions, and a strong oncology portfolio, despite ...

Bristol-Myers Squibb: Hold Rating Amid New Schizophrenia Drug Launch and Patent Expiries

Analyst Evan Seigerman from BMO Capital maintained a Hold rating on Bristol-Myers Squibb (BMY – Research Report) and increased the price ...

MarketWatch5d

2seventy, Bristol Myers Drop Abecma Study in Newly Diagnosed Patients

2seventy bio and Bristol Myers Squibb are pulling the plug on a late-stage study of their Abecma gene therapy in certain people newly diagnosed with the blood cancer multiple myeloma. 2seventy on ...

Seeking Alpha2d

Bristol Cobenfy approval draws optimism from Street, though with caveats

The U.S. FDA's approval Thursday of Bristol Myers Squibb's (NYSE:BMY) novel antipsychotic Cobenfy (xanomeline and trospium chloride) for schizophrenia could significant influence treatment of ...

Some results have been hidden because they may be inaccessible to you

Show inaccessible results